Research Peptide
Fast shipping
Same-day dispatch
Third-party tested
U.S. accredited labs
≥99% purity
HPLC verified
Research
This listing supplies CJC-1295 and Ipamorelin as a single co-formulated research preparation — two distinct synthetic peptides lyophilized together into one vial for in-vitro and preclinical laboratory work. CJC-1295 is a synthetic analog of the growth-hormone-releasing hormone (GHRH) sequence, built on the GRF(1-29) fragment with substituted residues that increase its resistance to enzymatic breakdown in aqueous and plasma-model conditions. Ipamorelin is a short synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified in the literature as a growth-hormone secretagogue that acts, in cell-based systems, at the ghrelin/GHS-R1a receptor rather than at the GHRH receptor. Because the two peptides engage separate receptor systems in vitro, they are frequently studied as a pair, and this blend supplies them pre-combined at a fixed ratio for that purpose.
As a combined material, the product is characterized as two independent molecular species that coexist in one lyophilized cake — not a conjugate or a single fused sequence. Each component retains its own molecular formula, monoisotopic mass, and chromatographic behavior. This distinction matters for identity work: an analyst confirming the blend expects to resolve two separate peaks and two separate mass signals, one for each peptide. All descriptions below concern the research substance itself, its documented study history, and standard handling of freeze-dried peptide reference material; they are not statements about outcomes in humans or animals.
The individual components of this blend have each been examined in cell-based and rodent-model literature, generally as tools for probing the somatotropic (GH) axis under controlled laboratory conditions. Published in-vitro work on GHRH analogs such as CJC-1295 has focused on receptor binding at the GHRH receptor and on stability profiling — how backbone substitutions slow degradation in serum-model assays. Ipamorelin has appeared in receptor-selectivity studies characterizing GHS-R1a engagement and its reported selectivity relative to other secretagogues in cultured pituitary-cell systems. These reports describe experimental laboratory observations only and do not establish any outcome in humans or animals.
These references describe experimental laboratory work only. They are not medical claims, are not evidence of safety or efficacy in humans or animals, and should not be interpreted as guidance for any use outside a controlled research environment. Research on these peptides remains preliminary and ongoing, and nothing here constitutes medical advice.
Each blended lot is supplied as a lyophilized powder and characterized before release using orthogonal analytical methods, with results documented on a lot-specific Certificate of Analysis (COA). Because this is a two-peptide preparation, characterization confirms both the identity of each component and their relative proportion, separating purity (how much of each species is the intended peptide) from identity (confirmation that each target is the correct molecule).
The COA tied to the lot number received is the definitive analytical record for that specific batch. Because purity, mass, and component ratio can vary slightly between synthesis and fill batches, researchers should reference the accompanying COA rather than generic specifications when documenting experimental inputs — this is especially important for a blend, where the ratio of the two peptides is part of the experimental variable. Retaining the COA alongside experimental records supports reproducibility and traceability.
The following describes conventional laboratory handling of lyophilized research peptides and is not instruction for human or animal use. As a freeze-dried peptide preparation, this blend is hygroscopic and sensitive to repeated temperature cycling. Standard laboratory practice is to allow the sealed vial to equilibrate to room temperature before opening to minimize condensation, then reconstitute with an appropriate research-grade solvent under aseptic technique. Because both peptides dissolve into the same working solution, aliquoting reconstituted stock into single-use portions is used to limit freeze-thaw cycles that can degrade either component and shift the effective ratio. Detailed temperature and stability windows for lyophilized, reconstituted, and working solutions appear in the storage table on this page.
It is a single vial containing two separate synthetic peptides co-lyophilized together: CJC-1295, a modified GHRH (GRF 1-29) analog, and Ipamorelin, a five-residue growth-hormone-secretagogue peptide. They are not fused or conjugated — each keeps its own sequence, molecular mass, and chromatographic identity. The material is supplied strictly as a combined reference preparation for in-vitro and laboratory research.
In the research literature the two are commonly studied as a pair because they engage different receptor systems in vitro — CJC-1295 as a GHRH-receptor analog and Ipamorelin as a ghrelin/GHS-R1a agonist. Supplying them pre-combined at a fixed nominal ratio gives researchers a consistent starting material when their protocol calls for both components rather than reconstituting and mixing two independent vials. This describes laboratory research use only, not any human or animal application.
Reversed-phase HPLC resolves the preparation into two distinct peaks so per-component purity can be integrated separately, and mass spectrometry (ESI-MS or MALDI-TOF) confirms two masses matching the theoretical values for CJC-1295 and Ipamorelin. The lot-specific COA documents both identities, the purity of each species, appearance, and the nominal component ratio, and is the authoritative analytical record for the exact material received.
CJC-1295 is described in the literature both with and without a Drug Affinity Complex (DAC) modification, which changes the molecular mass and stability profile. Because that distinction affects the expected mass on the COA, researchers should confirm the specific form and molecular weight against the lot-specific Certificate of Analysis and the molecular profile shown on this page rather than assuming a generic value.
Verified test results
Our lots are tested by Freedom Diagnostics, an independent U.S. laboratory — identity by LC-MS, purity by HPLC-UV, net content quantified. This is the most recent report the lab released for this compound, exactly as signed.
Certificate of Analysis
99.05%
Purity by HPLC-UV
Lot
AS-CIP10-2026-0009
Tested
Oct 13, 2026
Labeled
10mg blend
Measured
11.71 mg total
Lab panel · lot AS-CIP10-2026-0009
✓ All assays passedOpen any lot's signed certificate — the released report is always one tap away.
CJC-1295 + Ipamorelin Blend 10mg
LOT AS-CIP10-2026-0009
Identity, purity, and net content · Freedom Diagnostics, independent U.S. lab
View certificateThis product is sold strictly for in-vitro research and laboratory use only. It is not intended for human or animal consumption, diagnostic purposes, or therapeutic application.
By purchasing this product, you confirm that you are a qualified researcher operating within an appropriate laboratory environment and will use this compound in accordance with all applicable local, state, and federal regulations.
Amino Science Labs assumes no liability for misuse of this product outside of its intended research application.
Standard laboratory practice is to allow the sealed vial to reach room temperature before opening to prevent condensation on the hygroscopic powder, reconstitute using aseptic technique with a research-grade solvent, and aliquot the resulting stock to avoid repeated freeze-thaw cycles that could degrade either peptide and shift the ratio. Follow the temperature and time windows in the storage table on this page for lyophilized, reconstituted, and working solutions. These are laboratory handling notes only, not instructions for any human or animal use.
No. This material is supplied strictly for in-vitro and laboratory research use by qualified researchers. It is not a drug, supplement, or food, is not intended for human or animal consumption or any diagnostic or therapeutic purpose, and nothing on this page constitutes medical advice. Reported studies describe laboratory systems only and do not establish any human or animal outcome.
